Evgen Pharma Share Discussion Threads

[moneymunch] 30/9/2020 20:13

Scottish numbers: 30 September 2020 640 new cases of COVID-19 reported; this is 10.3% of newly tested individuals. 7 new reported death(s) of people who have tested positive 15 people were in intensive care yesterday with recently confirmed COVID-19. 137 people were in hospital yesterday with recently confirmed COVID-19. 15,629 new ;tests for COVID-19 that reported results.

[euclid5] 30/9/2020 19:59

Thnaks for that link - so not too long to wait for the results then?

[moneymunch] 30/9/2020 19:59

Euclid,who know's, but at 11.30p the 3 x 500k trades were at least 20p more than any other trades that day, and one would have thought they were priced as buys imho....and as I said earlier, all in the mix regardless and suggestive of an ongoing share transfer/accumulation....and as far as the Covid-19 patient trials are concerned, there was probably a shortage of patients initially, but that now looks like all has changed with the second wave rearing its ugly head, and so SFX-01's patient trials could be underway or will be very soon. Prof Chalmers website states it started 1/8/20 but still no confirmation of first patients being administered SFX-01, and because it's such a large and comprehensive trial, then obviously full results aren't expected until July next year, but that doesn't mean we would have to wait that long for an update....early reporting would be very likely if the drug was having a positive effect imho...or negative effect for that matter...Gl ;-) Ps plenty more in Evgen's pipeline which could add significant value, as well as a potential commercial JV at anytime....let's see what the new CEO has to report in due course. ;-)

[on target] 30/9/2020 19:21

https://www.lifearc.org/funding/covid-19-funding/sfx-01/"...The primary outcome of the trial is the clinical status of patients on day 15 based on a seven point scale..."

[bocker01] 30/9/2020 19:07

Euclid, I would expect them to update on progress. Key is the sample size. It’s big. Meaningful information should be available to those in the know fast.

[euclid5] 30/9/2020 19:02

Money M, how do you definately know those 3 x 500k were not sells, you don't know for certain - but I guess it's in the price now anyway Seen this on the LSE site - so do we have to wait until June 2021 until this trial ends before we know the resuts of SFX-01? StatusActive: Effective start/end date 1/08/20 → 31/07/21 hxxps://discovery.dundee.ac.uk/en/projects/a-randomized-controlled-trial-of-sfx-01-to-improve-clinical-outco

[bocker01] 30/9/2020 17:13

Just suffering Mesquida! No immunity!

[mesquida] 30/9/2020 16:57

"Never like seeing losses", Bocker ! As a long suffering shareholder in Iofina I would have thought that by now you might have developed a degree of immunity to losses !!!

[jusjusjus] 30/9/2020 16:39

I think when the bid was below 11p the offer was around 11.1, so we have fewer sells than what's being reported

[bocker01] 30/9/2020 16:19

Strength of the pipeline is so important. Good luck to them. Never like seeing losses.

[moneymunch] 30/9/2020 15:17

It's a shame for those investors sitting on a loss ( wherever invested ), but obviously after hitting a market cap of £370m from c£30m or so, then they obviously needed some very good news to sustain and push on, and so the retrace looked inevitable...i've not reasearched SNG and so no idea what else is in their pipeline but i'm sure when they get the green light for the next Phase for their Covid trials, then the share price will bounce big again. Gl ;-)

[peanut100] 30/9/2020 15:00

Shame about SNG

[moneymunch] 30/9/2020 14:46

ps all in the mix regardless, but suggestive of a share transfer/accumulation imho.....and i'll be surprised if there's any significant number of shares left in free float at all, judging by the on-going tading activity of some very large trades that has been going on for months.....hopefully all will be revealed in the coming weeks with the new CEO in place. Gl ;-)

[euclid5] 30/9/2020 14:34

The 2 x 500,000 at 11.30p look like a roll over or a sell

[notknowing] 30/9/2020 11:21

Code 4 = 10 Bagger

[jusjusjus] 30/9/2020 11:21

"4" trade must be an MM signal, you can't buy 4 shares and be offered full price!

[jusjusjus] 30/9/2020 10:42

maybe the transfer is the new CEO taking a healthy position? nah, that's daft, not before he officially starts

[stockhunters] 30/9/2020 10:28

i am amazed this has not had more interest since the ceo appointment in my eyes it gives the greenlight for an update at this tiny market cap this is one of the smallest available in the sector

[moneymunch] 30/9/2020 10:20

and maybe disclosure on the relentless share transfer/accumulation, which possibly could be suggestive of a strategic investor JV partnership imho...Gla :-)

[jusjusjus] 30/9/2020 10:13

CEO arrives in a few days, hopefully at least an update from him for the interim period closing 30th Sept.

[notknowing] 30/9/2020 10:09

Rerate MKT CAP to 50m then 100M

[stockhunters] 30/9/2020 10:07

market makers taking it back up ceo on board come on let us see that sfx update!

[moneymunch] 30/9/2020 09:51

SFX-01's Covid-19 patient trials are phase2/3...Gl ;-) University of Dundee to establish potential of investigational compound to improve outcomes in COVID-19 progression in trial of 300 patients Research title A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in COVID-19 progression Summary University of Dundee and Evgen Pharma PLC, with funding from LifeArc, are set to commence clinical trial testing of an investigational medicinal product in 300 hospitalised COVID-19 patients. Researchers have identified that one of Evgen’s existing products, SFX-01, could reduce the impact of COVID-19 disease by preventing Acute Respiratory Distress Syndrome (ARDS), a common and often deadly symptom of severe cases of COVID-19. Research organisations University of Dundee Evgen Pharma PLC Researchers Principal Investigator: Professor James Chalmers, University of Dundee  Co-investigators: Albena Dinkova-Kostova, University of DundeePotential of repurposed therapeutic for COVID-19 pandemic A major challenge in the treatment of COVID-19 is the development of slowly worsening lung damage, known as Acute Respiratory Distress Syndrome (ARDS). This requires intensive care treatment with ventilation until the inflammation is resolved and the lungs can heal. Nrf2 is a transcription factor (a naturally-occurring protein) which forms part of the body’s defences against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. It is hypothesised that increasing the levels of active Nrf2 in patients with COVID-19 could improve recovery and prevent the need for ventilation. SFX-01, a stable form of the natural compound sulforaphane, is an orally administered investigational medicinal product that activates Nrf2 and has been tested in over 130 patients to date in clinical trials (in healthy volunteers and patients suffering from breast cancer or a rare type of brain haemorrhage). Researchers secured funding from LifeArc to conduct an investigator led, prospective, randomised, double-blind placebo-controlled trial, conducted in the UK, of patients hospitalised with COVID-19. Investigating a sample size of 300 subjects, the study will compare outcomes for 300mg SFX-01 taken orally, once daily, plus best standard of care (BSC) versus placebo taken orally, once daily plus BSC. The primary outcome of the trial is the clinical status of patients on day 15 based on a seven point scale, recommended by the World Health Organisation as the optimal clinical trial endpoint for COVID-19 studies. The trial will be conducted in up to six sites across Scotland and the north of England with first patient visit anticipated to happen in July.